84 related articles for article (PubMed ID: 15823732)
1. Association of skin rash and tumor response to HER1/EGFR inhibition: does HER1 stimulated tumor growth depend on circulatory instead of paracrine ligands?
Kurbel S; Faj D
Med Hypotheses; 2005; 64(6):1244-5. PubMed ID: 15823732
[No Abstract] [Full Text] [Related]
2. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Peréz-Soler R; Saltz L
J Clin Oncol; 2005 Aug; 23(22):5235-46. PubMed ID: 16051966
[TBL] [Abstract][Full Text] [Related]
3. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
Bishop PC; Myers T; Robey R; Fry DW; Liu ET; Blagosklonny MV; Bates SE
Oncogene; 2002 Jan; 21(1):119-27. PubMed ID: 11791182
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
5. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
[TBL] [Abstract][Full Text] [Related]
6. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
7. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
8. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Reimer G; Brudler O; Heinrich B; Bangerter M
MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
[No Abstract] [Full Text] [Related]
9. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
Marshall J
Cancer; 2006 Sep; 107(6):1207-18. PubMed ID: 16909423
[TBL] [Abstract][Full Text] [Related]
10. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
Mutsaers AJ; Francia G; Man S; Lee CR; Ebos JM; Wu Y; Witte L; Berry S; Moore M; Kerbel RS
Clin Cancer Res; 2009 Apr; 15(7):2397-405. PubMed ID: 19276250
[TBL] [Abstract][Full Text] [Related]
12. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
14. EGFR as a target: rationale for therapy.
Wujcik D
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):5-9. PubMed ID: 16616281
[TBL] [Abstract][Full Text] [Related]
15. On receptor inhibitors and chemotherapy.
Ryan PD; Chabner BA
Clin Cancer Res; 2000 Dec; 6(12):4607-9. PubMed ID: 11156209
[No Abstract] [Full Text] [Related]
16. [New approaches to antitumor therapy: the use of preparations acting on processes regulated by epidermal and/or alpha-transforming growth factors].
Kushlinskiĭ NE; Gershteĭn ES
Eksp Klin Farmakol; 1996; 59(1):74-80. PubMed ID: 8704642
[No Abstract] [Full Text] [Related]
17. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Memon AA; Sorensen SB; Nexo E
Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
[TBL] [Abstract][Full Text] [Related]
18. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
Albanell J; Codony-Servat J; Rojo F; Del Campo JM; Sauleda S; Anido J; Raspall G; Giralt J; Roselló J; Nicholson RI; Mendelsohn J; Baselga J
Cancer Res; 2001 Sep; 61(17):6500-10. PubMed ID: 11522647
[TBL] [Abstract][Full Text] [Related]
19. Involvement of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro.
Morishige K; Kurachi H; Amemiya K; Adachi H; Inoue M; Miyake A; Tanizawa O; Sakoyama Y
Cancer Res; 1991 Nov; 51(21):5951-5. PubMed ID: 1718591
[TBL] [Abstract][Full Text] [Related]
20. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
Iyer R; Bharthuar A
Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
